KRAS and neoplasm: Heinemann and colleagues [58] investigated the comparative effectiveness of cetuximab and the anti-vascular epidermal growth factor-A (VEGF-A) antibody bevacizumab in combination with the chemotherapy regimen (FOLFIRI) in the FIRE-3 study, which included 592 patients with KRAS exon 2 wild-type tumours.